Latest research on Xolair

A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.

Xolair side effects

Increases in these proteins correspond with our prior observations confirming statistically significant increases in proteins with similar function, Ig kappa chain C region, Ig gamma-1 chain C region and Ig lambda-2 chain C regions 34. [source, 2015]
While it would appear that Xolair has potentially severe side effects, it must be remembered that anaphylaxis and cancer formation occurred only in a very small number of patients. [source, 2015]
Recently, the Xolair Pregnancy Registry (EXPECT) has been published,36 in which 188 of 191 pregnant women were exposed to omalizumab (indicated by asthma) during their first trimester, with no apparent increased birth prevalence or patterns of major anomalies. [source, 2015]
Identified proteins with increased abundance (n = 14) in MS (table 2 and table e-2) were the following: amyloid-like protein 2 (2/2, 2 significant peptides for a total of 2 peptides), neurofascin (3/3), carboxypeptidase E (2/3), neuronal growth regulator 1 (2/3), contactin-2 (4/9), amyloid beta A4 (6/11), brevican core protein (5/7), disintegrin and metalloproteinase domain-containing protein 22 (2/2), tyrosine-protein phosphatase non-receptor type substrate 1 (3/4), dickkopf-related protein 3 (6/11), neuronal cell adhesion molecule (9/18), Ig kappa chain V-III region POM (2/2), Ig gamma-1 chain C region (5/11), and kallikrein-6 (4/7). [source, 2015]
Thus, the majority of proteins with increased abundance in our MS group (compared to the monophasic ADS group) were neuronal-related, with the exception of 2 immune function–related proteins (Ig gamma-1 chain C region and Ig kappa chain V-III region POM) (table 3). [source, 2015]
Treatment of asthmatic children and adults with a monoclonal humanized anti-IgE antibody, omalizumab (Xolair) decreased FENO levels [3,4] and elevated FENO levels can help predicting the response to this treatment [5]. [source, 2013]
Protein therapies such as anti-IgE monoclonal antibody omalizumab (Xolair) for treating allergic airway constriction [1] and TNFα inhibitors in the field of rheumatoic arthritis and chronic inflammatory conditions [2] have shown their high effectiveness, but they can induce side-effects and are expensive therapies. [source, 2011]